2. Academic Validation
  3. Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability

Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability

  • Eur J Med Chem. 2023 May 5;251:115244. doi: 10.1016/j.ejmech.2023.115244.
Kaluvu Balaraman 1,  Emre Deniz 2,  Eryn Nelson 3,  Samantha L Pilicer 3,  Sezen Atasoy 2,  Anna Molotkova 2,  Handan Sevim 2,  Purushottam B Tiwari 2,  Aykut Üren 4,  Christian Wolf 5
Affiliations

Affiliations

  • 1 Chemistry Department, Georgetown University, Washington, DC, 20057, USA; Medicinal Chemistry Shared Resource (MCSR), Georgetown University Medical Center, Washington, DC, USA.
  • 2 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
  • 3 Chemistry Department, Georgetown University, Washington, DC, 20057, USA.
  • 4 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. Electronic address: au26@georgetown.edu.
  • 5 Chemistry Department, Georgetown University, Washington, DC, 20057, USA; Medicinal Chemistry Shared Resource (MCSR), Georgetown University Medical Center, Washington, DC, USA. Electronic address: cw27@georgetown.edu.
PMID: 36917882 DOI: 10.1016/j.ejmech.2023.115244
Abstract

Ewing Sarcoma (ES) is a Cancer of bone and soft tissues affecting mostly children and young adults. Aggressive progression and poor prognosis of this malignancy call for novel and targeted treatments. CD99 is a transmembrane protein that is abundantly expressed on ES cells and is a diagnostic marker for the disease. ES cells are selectively sensitive to CD99 inhibition compared to most normal cells and other tumors. Therefore, CD99 is a good molecular target for ES treatment. Clofarabine and cladribine are two FDA approved drugs that are administered for their inhibitory acts on DNA synthesis to treat relapsed or refractory acute lymphoblastic and myeloid leukemia. They have also been shown to directly bind to CD99 and inhibit ES growth through a distinct mechanism. In the current study, we designed, synthesized and tested new ES specific derivatives of both drugs that would continue to target CD99 but with expected reduction in cellular membrane permeability and rendered unsuitable for inhibiting DNA synthesis. By using commercially available clofarabine and cladribine purine nucleoside analogs, we modified the primary alcohol moiety at the deoxyribose C-5' terminal site to suppress phosphorylation and thus inhibition of subsequent DNA synthesis pathways. In addition, we incorporated a variety of polar groups in the ribose and purine rings to reduce membrane permeability and investigated the effects of configurational changes in the sugar moiety. Among 26 new derivatives, we identified two compounds, BK50164 and BK60106, that cause cell death specifically in ES primarily due to inhibition of CD99 but not via inhibition of DNA synthesis. These findings provide a road map for the future development selective CD99 inhibitors for targeted treatment of ES.

Keywords

CD99 inhibitors; Cladribine; Clofarabine; Ewing sarcoma; Nucleoside derivatization; Targeted therapy.

Figures
Products